中东呼吸综合征冠状病毒
病毒学
中东呼吸综合征
2019年冠状病毒病(COVID-19)
抗体
倍他科诺病毒
医学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019-20冠状病毒爆发
中和抗体
呼吸系统
免疫学
冠状病毒
冠状病毒感染
病理
爆发
内科学
传染病(医学专业)
疾病
作者
Peihua Niu,Senyan Zhang,Pan-Pan Zhou,Baoying Huang,Yao Liang Deng,Kun Qin,Pengfei Wang,Wenling Wang,Xinquan Wang,Jianfang Zhou,Linqi Zhang,Wenjie Tan
标识
DOI:10.1093/infdis/jiy311
摘要
Background: The Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection with a high (~35%) mortality rate. Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease. Methods: We describe the germline diversity and neutralizing activity of 13 potent human monoclonal antibodies (mAbs) that target the MERS-CoV spike (S) protein. Biological functions were assessed by live MERS-CoV, pseudotype particle and its variants, and structural basis was also determined by crystallographic analysis. Results: Of the 13 mAbs displaying strong neutralizing activity against MERS-CoV, two with the immunoglobulin heavy-chain variable region (IGHV)1-69-derived heavy chain (named MERS-GD27 and MERS-GD33) showed the most potent neutralizing activity against pseudotyped and live MERS-CoV in vitro. Mutagenesis analysis suggested that MERS-GD27 and MERS-GD33 recognized distinct regions in S glycoproteins, and the combination of 2 mAbs demonstrated a synergistic effect in neutralization against pseudotyped MERS-CoV. The structural basis of MERS-GD27 neutralization and recognition revealed that its epitope almost completely overlapped with the receptor-binding site. Conclusions: Our data provide new insights into the specific antibody repertoires and the molecular determinants of neutralization during natural MERS-CoV infection in humans. This finding supports additional efforts to design and develop novel therapies to combat MERS-CoV infections in humans.
科研通智能强力驱动
Strongly Powered by AbleSci AI